Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 23Lymphoma, Large B-Cell, Diffuse 17Recurrence 7Neoplasms, Plasma Cell 5Lymphoma, T-Cell, Peripheral 4Lymphoma, Mantle-Cell 4Leukemia, Myeloid, Acute 4Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, B-Cell 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Paraproteinemias 2Neoplasms by Histologic Type 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Hematologic Diseases 2Colorectal Neoplasms 2Blood Protein Disorders 2Sezary Syndrome 1Renal Insufficiency 1Neuroblastoma 1Mycosis Fungoides 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

daratumumab 1Lenalidomide 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Corneal Diseases × Lenalidomide × Clear all
NCT05280275 2023-12-01

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

Hellenic Society of Hematology

Phase 1/2 Unknown
36 enrolled
Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡